Who Paid My Doc
Sarah Doernberg
Internal Medicine San Francisco, CA Medical Doctor
NPI 1245406628 CMS profile 427325
Ucsf Department Of Medicine, 505 Parnassus Ave, Room M987, San Francisco, CA 94143
General payments
$6,209
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$91,790
Through program year 2025, Sarah Doernberg of San Francisco, CA is reported in the CMS Open Payments database as having received $6,209 across 4 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $91,790 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,529 | 2 | |
| 2022 | General | $450 | 1 | |
| 2019 | General | $3,230 | 1 |
Beside peers
- Sarah Doernberg
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to Sarah Doernberg were reported at $2,529. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | Sarah Doernberg | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,230 | $159 | $48–$570 | $163 |
| 2020 | $0 | $119 | $33–$402 | $114 |
| 2021 | $0 | $135 | $37–$521 | $132 |
| 2022 | $450 | $141 | $42–$496 | $149 |
| 2023 | $0 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $2,529 | $156 | $47–$551 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
192
Drug cost
$432,571
Branded share of claims
33.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Arikayce Amikacin Liposomal/Neb.Accessr | Brand | 13 | $188,065 | |
| Sivextro Tedizolid Phosphate | Brand | 12 | $151,474 | |
| Sirturo Bedaquiline Fumarate | Brand | 14 | $53,896 | |
| Posaconazole | Generic | 17 | $34,053 | |
| Methenamine Hippurate | Generic | 18 | $993 | |
| Minocycline Hcl | Generic | 19 | $923 | |
| Rifampin | Generic | 13 | $765 | |
| Ethambutol Hcl | Generic | 16 | $748 | |
| Doxycycline Hyclate | Generic | 17 | $588 | |
| Amoxicillin | Generic | 15 | $440 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 19 billing codesPaid by Medicare
$31,627
Medicare patients
128
Services billed
460
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 54% | |
| Arthritis | 49% | |
| Diabetes | 45% | |
| Heart failure | 37% | |
| Ischemic heart disease | 36% | |
| Atrial fibrillation | 36% | |
| Depression | 36% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in California
Andrew Cheng
Internal Medicine · South San Francisco, CA
Tung Ngo
Internal Medicine · Newport Beach, CA
Christian Eversull
Internal Medicine · Stanford, CA
Christian Sandrock
Internal Medicine · Sacramento, CA
Hatim Husain
Internal Medicine · San Diego, CA
Teck Ling
Internal Medicine · Palo Alto, CA
Related records
Internal Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.